Skip to content

MDMA and psychedelic-assisted therapy for PTSD

TL;DR — Two sponsor-linked phase 3 trials found MDMA-assisted therapy superior to therapy with inactive placebo: d=.91 in 90 severe-PTSD participants and d=.70 in 104 moderate–severe participants (Mitchell 2021, PMID 33972795) (Mitchell 2023, PMID 37709999). These are efficacy signals, not regulatory approval. As of live PubMed searches on 2026-09-02, the FDA declined to approve MDMA-assisted therapy in August 2024 for insufficient evidence and required a further phase 3 trial, and no approval has been reported since (Wolfgang 2025, PMID 39741438) (Morland 2026, PMID 41820235). Functional unblinding, expectancy, therapist effects, misconduct allegations and the inseparability of drug from psychotherapy remain central interpretive issues. Psilocybin and depression/pooled anxiety findings are not PTSD evidence.

What was tested

The phase 3 package tested MDMA plus a manualized therapeutic program against identical therapy plus inactive placebo, not MDMA alone (Mitchell 2021, PMID 33972795) (Mitchell 2023, PMID 37709999). Attribution to drug, psychotherapy, interaction and expectancy remains difficult.

Efficacy

MAPP1 mean CAPS-5 change among completers was −24.4 versus −13.9 and between-group d=.91 (Mitchell 2021, PMID 33972795). MAPP2 least-squares changes were −23.7 versus −14.8 and d=.70 (Mitchell 2023, PMID 37709999).

Blinding

Acute subjective effects make functional unblinding likely. Blinded independent outcome assessors reduce but do not eliminate expectancy transmitted through participants and therapists; the 2026 state-of-the-science review names blinding failure, absent active comparators, no head-to-head comparison of therapy models, inadequate safety monitoring and limited sample generalizability as the five limitations the field must resolve (Morland 2026, PMID 41820235). The FDA advisory committee's deliberations turned on the same benefit–risk questions (Marks 2024, PMID 39078646). Active-placebo and expectancy measurement strategies remain underdeveloped.

Safety

Controlled settings include medical screening, monitored dosing and integration. Small trials cannot precisely estimate rare harms; protocol deviations and therapist conduct are part of intervention safety, not externalities.

Regulation

FDA advisory review concerned benefit–risk (Marks 2024, PMID 39078646). MDMA-assisted therapy received FDA Breakthrough Therapy designation for PTSD in 2017; the agency then declined to approve it in August 2024 on grounds of insufficient evidence and required an additional phase 3 trial (Wolfgang 2025, PMID 39741438) (Morland 2026, PMID 41820235). No approval should be inferred from breakthrough designation or positive trials. A 2026 meta-analysis pooling eight randomized trials (k=24 comparisons) estimated MDMA-assisted therapy reduced PTSD symptom severity by SMD −1.19 (95% CI −1.95 to −0.42; n=298, k=9; I²=68.8%), reduced dissociative symptoms (SMD −0.37, 95% CI −0.70 to −0.04) and may improve functioning (SMD −0.83, 95% CI −1.47 to −0.19), with no clear benefit for depressive symptoms; most studies were at high risk of bias in outcome measurement (Fares-Otero 2026, PMID 41825162).

Other psychedelics and ketamine

Psilocybin. A 2022 review stated that no study had then investigated psilocybin or psilocybin-assisted psychotherapy as a treatment for PTSD (Khan 2022, PMID 35711024). That absence has since closed, and re-running the search on 2026-09-02 is what establishes the current position. Two uncontrolled PTSD trials are now published: a phase 2, non-randomized, open-label multicentre trial of single-dose psilocybin in 22 participants, which reported 117 treatment-emergent adverse events (none serious), and a mean CAPS-5 change of −29.9 (SD 14.06) at week 4 and −29.5 (SD 15.43) at week 12 (McGowan 2026, PMID 40883964); and an open-label pilot of psilocybin-assisted therapy in 12 US veterans with severe treatment-resistant PTSD, reporting a mean clinician-rated reduction of 27.5 points (95% CI 19.9–35.1; d=2.30, P<0.001) at one month with 75% in remission and no increase in suicidal ideation (Armstrong 2026, PMID 42533157, NCT05554094). Both are single-arm designs with no control condition, so the dated evidence gap is now narrower and more specific: as of 2026-09-02 no randomized, controlled trial of psilocybin for PTSD has been published, and the two open-label studies together enrolled 34 participants. A pooled psychedelic meta-analysis across mental disorders still cannot supply a PTSD-specific psilocybin effect (Yao 2024, PMID 38574699).

Ketamine. Depression findings should not be imported (Stein 2021, PMID 33517752), but PTSD-specific randomized evidence exists and disagrees with itself. Six ketamine (0.5 mg/kg) versus midazolam infusions over two weeks in 30 adults with chronic PTSD reduced CAPS-5 by 11.88 points more than midazolam (SE 3.96; d=1.13, 95% CI 0.36–1.91), with 67% versus 20% responders (Feder 2021, PMID 33397139). Eight infusions of placebo, 0.2 mg/kg or 0.5 mg/kg ketamine in 158 antidepressant-resistant veterans and service members produced no significant group-by-time effect on PCL-5 or CAPS-5, while the standard dose still improved MADRS depression scores (Abdallah 2022, PMID 35046508). Population, dose schedule and comparator all differ; the discrepancy is unresolved.

Other rapid-acting agents. A phase 2 randomized, placebo-controlled trial across 16 sites in the US, UK and Ireland tested the neuroplastogen TSND-201 (methylone) in 65 adults with PTSD without any psychotherapy component and found a least-squares mean CAPS-5 difference of 9.64 favouring drug (90% CI −16.48 to −2.80; P=.01), with PCL-5, SDS and MADRS moving in the same direction (Jones 2026, PMID 41706459, NCT05741710). It is sponsor-run, reports 90% rather than 95% intervals, and has not been replicated — but it separates a rapid-acting drug effect from a therapy package in a way the MDMA programme has not.

Conflicts and independence

Sponsor involvement and a specialised therapy ecosystem heighten the need for independent replication, transparent adverse-event adjudication and fidelity monitoring.

Quantitative anchors

Measure Estimate Population/method Source
MAPP1 n=90; CAPS-5 d=.91; SDS d=.43 Severe PTSD; NCT03537014 (Mitchell 2021, PMID 33972795)
MAPP2 n=104; CAPS-5 d=.70; SDS d=.40 Moderate–severe PTSD; NCT04077437 (Mitchell 2023, PMID 37709999)
Severe TEAEs, MAPP2 5/53 vs 2/51 No deaths or serious TEAEs reported (Mitchell 2023, PMID 37709999)
Regulatory status FDA rejected initial NDA in 2024 Additional phase 3 required (Wolfgang 2025, PMID 39741438)
Phase 2 service population randomized dose-response Veterans, firefighters, police (Mithoefer 2018, PMID 29728331)
MDMA-AT pooled SMD −1.19 (95% CI −1.95 to −0.42); I²=68.8% 8 RCTs; n=298 for the symptom outcome (Fares-Otero 2026, PMID 41825162)
Psilocybin, open-label phase 2 CAPS-5 −29.9 (SD 14.06) at week 4 n=22; no control arm (McGowan 2026, PMID 40883964)
Psilocybin, veteran pilot −27.5 points (95% CI 19.9–35.1); d=2.30 n=12; open-label; treatment-resistant (Armstrong 2026, PMID 42533157)
Repeated ketamine vs midazolam CAPS-5 −11.88 (d=1.13, 95% CI 0.36–1.91) n=30 (Feder 2021, PMID 33397139)
Repeated ketamine, multi-site null on PCL-5 and CAPS-5 n=158 veterans/service members (Abdallah 2022, PMID 35046508)
TSND-201 (methylone) CAPS-5 LS mean difference 9.64 (90% CI −16.48 to −2.80) n=65; no psychotherapy component (Jones 2026, PMID 41706459)

Evidence ledger

The ledger lists the live-retrieved records used to bound this page. Inclusion does not make every record equally probative; design, population and comparator remain decisive.

PMID Year Evidence contribution Scope caution
33972795 2021 MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. PTSD-specific record; inspect design and population
37709999 2023 MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. PTSD-specific record; inspect design and population
29728331 2018 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. PTSD-specific record; inspect design and population
39741438 2025 MDMA and MDMA-Assisted Therapy. PTSD-specific record; inspect design and population
36402502 2023 Post-traumatic Stress Disorder. PTSD-specific record; inspect design and population
37132142 2024 Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review. Synthesis: preserve included-population and certainty limits
38284341 2024 The Psychedelic Future of Post-Traumatic Stress Disorder Treatment. PTSD-specific record; inspect design and population
32098487 2020 Psychedelics and Psychedelic-Assisted Psychotherapy. PTSD-specific record; inspect design and population
35711024 2022 Psilocybin for Trauma-Related Disorders. PTSD-specific record; inspect design and population
38574699 2024 Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Synthesis: preserve included-population and certainty limits
40308104 2025 An Update on Psychotherapy for the Treatment of PTSD. PTSD-specific record; inspect design and population
38198456 2024 Effects of MDMA-assisted therapy for PTSD on self-experience. PTSD-specific record; inspect design and population
39078646 2024 Psychedelic Therapy Scrutinized by FDA Advisory Committee? PTSD-specific record; inspect design and population
38795401 2024 Pharmacotherapy for sleep disturbances in post-traumatic stress disorder (PTSD): A network meta-analysis. Synthesis: preserve included-population and certainty limits
37615227 2023 Psychedelic drugs in the treatment of psychiatric disorders (Danish-language review). PTSD-specific record; inspect design and population
33517752 2021 Ketamine for PTSD: Well, Isn't That Special. PTSD-specific record; inspect design and population
39032491 2024 Ketamine ameliorates post-traumatic social avoidance by erasing the traumatic memory encoded in VTA-innervated BLA engram cells. PTSD-specific record; inspect design and population
33053043 2021 MDMA-assisted psychotherapy for the treatment of PTSD. PTSD-specific record; inspect design and population
29356590 2018 Taking Psychedelics Seriously. PTSD-specific record; inspect design and population
34708874 2022 MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis. Synthesis: preserve included-population and certainty limits
39381877 2024 MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs). Synthesis: preserve included-population and certainty limits
33397139 2021 A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. PTSD-specific record; inspect design and population
35688992 2022 Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder. PTSD-specific record; inspect design and population
37991966 2023 PHARMACOLOGY OF POST-TRAUMATIC STRESS DISORDER. PTSD-specific record; inspect design and population
38941125 2024 Clonidine for post-traumatic stress disorder: a systematic review of the current evidence. Synthesis: preserve included-population and certainty limits
32063234 2020 Psychological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Synthesis: preserve included-population and certainty limits
41820235 2026 State of the Science: MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder. Narrative review; records the August 2024 FDA decision
41825162 2026 Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes. High risk of bias in outcome measurement across included trials
40883964 2026 Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial. Open-label, no control arm; safety was the primary outcome
42533157 2026 Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial. n=12; open-label pilot; not an efficacy estimate
33397139 2021 A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Small RCT; psychoactive placebo comparator
35046508 2022 Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Null primary outcome; antidepressant-resistant population
41706459 2026 Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial. Phase 2; sponsor-employed authors; 90% CIs

Interpretation guardrails

  • Trauma exposure, post-traumatic symptoms, acute stress disorder, DSM-5 PTSD, ICD-11 PTSD and ICD-11 complex PTSD are not interchangeable populations.
  • A mixed-anxiety or transdiagnostic estimate is labelled as such; only a source’s PTSD stratum can be treated as a PTSD effect.
  • Comorbid depression is measured separately and cross-linked to the depression condition; it is not absorbed into PTSD.
  • Waitlist, treatment-as-usual, attention control and active treatment answer different causal questions.
  • Registration, statistical significance and diagnostic loss do not respectively prove completion, clinical importance or functional recovery.
  • This page synthesizes research and does not provide individual medical advice.

Minimum extraction frame for studies on this topic

Field What must be retained Why it changes interpretation
Diagnostic system DSM version, ICD version, full/subthreshold Case mix is not interchangeable
Diagnostic method Structured interview, clinician judgment, self-report cutoff Screening is not diagnosis
Index trauma Type, timing, repetition, direct/indirect/occupational Conditional risk and phenotype differ
Population Civilian, veteran, refugee, child/adolescent, mixed Transportability is empirical
Baseline severity Mean, SD, range and exclusion threshold Ceiling and floor effects alter change
CPTSD status ITQ/ICD-11 definition and DSO score Complexity cannot be inferred from trauma count
Comorbidity Depression, GAD, SUD, pain, TBI measured separately Shared symptoms can distort effects
Comparator Waitlist, usual care, attention, active treatment The estimand changes with comparator
Treatment dose Sessions offered/attended, duration, homework Assignment is not exposure
Outcome Symptoms, diagnosis, response, function, sleep Outcomes are not interchangeable
Time point End point and prespecified follow-up windows Acute benefit may not persist
Missing data Denominator, reasons, imputation and estimand Attrition can bias rank and magnitude
Adverse events Definitions, ascertainment and arm-level counts Absence of reporting is not absence of harm
Therapist/context Training, fidelity, allegiance, setting Delivery is part of the intervention
Funding/conflicts Sponsor role and analytic independence Especially material for proprietary packages

Claims this page does not make

  • It does not infer PTSD from trauma exposure alone.
  • It does not treat a self-report cutoff as equivalent to a structured diagnosis.
  • It does not convert a pooled anxiety-disorder effect into a PTSD effect.
  • It does not convert a depression outcome in a comorbid sample into a PTSD outcome.
  • It does not infer superiority from a statistically significant within-group change.
  • It does not infer equivalence from a non-significant between-group test.
  • It does not infer effectiveness from trial registration or mechanistic plausibility.
  • It does not assume military, civilian, refugee and pediatric estimates transport unchanged.
  • It does not average conflicting estimates that use different definitions.
  • It does not treat lack of adverse-event reporting as evidence of safety.

Evidence-updating triggers

Trigger Required response
New diagnostic revision Recalculate which populations prior estimates represent
New head-to-head RCT Compare against active treatment, not only waitlist
New individual-participant synthesis Revisit effect modifiers and transportability
Registry status change Verify results and linked publication before changing conclusions
Guideline update Separate evidence review from panel recommendation
Regulatory decision Record decision date and source; do not infer from efficacy papers
Safety signal Re-extract denominator, ascertainment and exposure time by arm
Contradictory replication Display estimates side by side; do not average definitions

Evidence updates should preserve the prior estimate and explain why the new study changes—or does not change—the inference.

Open questions

  • Can an independently funded phase 3 trial replicate benefit with credible expectancy measurement? (Wolfgang 2025, PMID 39741438)
  • Which part of the package—drug, therapy, interaction or context—drives durable benefit? (Mitchell 2021, PMID 33972795)
  • What are rare and long-term harms under real-world delivery? (Mitchell 2023, PMID 37709999)

References

  1. Mitchell JM, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025-1033. PMID 33972795
  2. Mitchell JM, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29(10):2473-2480. PMID 37709999
  3. Mithoefer MC, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018;5(6):486-497. PMID 29728331
  4. Wolfgang AS, et al. MDMA and MDMA-Assisted Therapy. Am J Psychiatry. 2025;182(1):79-103. PMID 39741438
  5. Merians AN, et al. Post-traumatic Stress Disorder. Med Clin North Am. 2023;107(1):85-99. PMID 36402502
  6. Burback L, et al. Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review. Curr Neuropharmacol. 2024;22(4):557-635. PMID 37132142
  7. Zaretsky TG, et al. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment. Curr Neuropharmacol. 2024;22(4):636-735. PMID 38284341
  8. Reiff CM, et al. Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry. 2020;177(5):391-410. PMID 32098487
  9. Khan AJ, et al. Psilocybin for Trauma-Related Disorders. Curr Top Behav Neurosci. 2022;56:319-332. PMID 35711024
  10. Yao Y, et al. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;335:115886. PMID 38574699
  11. Rothbaum BO, et al. An Update on Psychotherapy for the Treatment of PTSD. Am J Psychiatry. 2025;182(5):424-437. PMID 40308104
  12. van der Kolk BA, et al. Effects of MDMA-assisted therapy for PTSD on self-experience. PLoS One. 2024;19(1):e0295926. PMID 38198456
  13. Marks M Psychedelic Therapy Scrutinized by FDA Advisory Committee? JAMA. 2024;332(12):963-964. PMID 39078646
  14. Lappas AS, et al. Pharmacotherapy for sleep disturbances in post-traumatic stress disorder (PTSD): A network meta-analysis. Sleep Med. 2024;119:467-479. PMID 38795401
  15. Ibrahim IB, et al. Psychedelic drugs in the treatment of psychiatric disorders. [Danish] Ugeskr Laeger. 2023;185(32):V01230066. PMID 37615227
  16. Stein MB, et al. Ketamine for PTSD: Well, Isn't That Special. Am J Psychiatry. 2021;178(2):116-118. PMID 33517752
  17. Li M, et al. Ketamine ameliorates post-traumatic social avoidance by erasing the traumatic memory encoded in VTA-innervated BLA engram cells. Neuron. 2024;112(18):3192-3210.e6. PMID 39032491
  18. Reiff CM, et al. MDMA-assisted psychotherapy for the treatment of PTSD. Braz J Psychiatry. 2021;43(2):123-124. PMID 33053043
  19. Byock I Taking Psychedelics Seriously. J Palliat Med. 2018;21(4):417-421. PMID 29356590
  20. Smith KW, et al. MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis. J Clin Pharmacol. 2022;62(4):463-471. PMID 34708874
  21. Shahrour G, et al. MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs). Neuropsychopharmacol Rep. 2024;44(4):672-681. PMID 39381877
  22. Feder A, et al. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry. 2021;178(2):193-202. PMID 33397139
  23. Geldenhuys C, et al. Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder. CNS Drugs. 2022;36(7):721-737. PMID 35688992
  24. Tregub T, et al. PHARMACOLOGY OF POST-TRAUMATIC STRESS DISORDER. Georgian Med News. 2023;(342):122-124. PMID 37991966
  25. Marchi M, et al. Clonidine for post-traumatic stress disorder: a systematic review of the current evidence. Eur J Psychotraumatol. 2024;15(1):2366049. PMID 38941125
  26. Mavranezouli I, et al. Psychological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med. 2020;50(4):542-555. PMID 32063234
  27. Morland LA, et al. State of the Science: MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder. J Trauma Stress. 2026;39(2):173-187. PMID 41820235
  28. Fares-Otero NE, et al. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes. Eur Neuropsychopharmacol. 2026;107:112802. PMID 41825162
  29. McGowan NM, et al. Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial. J Psychopharmacol. 2026;40(1):139-148. PMID 40883964
  30. Armstrong SB, et al. Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial. Commun Med (Lond). 2026;6(1):411. PMID 42533157
  31. Abdallah CG, et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022;47(8):1574-1581. PMID 35046508
  32. Jones A, et al. Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial. JAMA Psychiatry. 2026;83(5):469-477. PMID 41706459